BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Key Points

• BTIG Research reaffirmed its Buy rating on Gain Therapeutics with a $5.00 price target, implying 142.72% potential upside from the reported $2.06 share price.
• Analyst sentiment is broadly positive: five analysts rate the stock Buy and one rates it Sell, resulting in a “Moderate Buy” consensus and an average price target of $7.50.
• Gain Therapeutics reported a quarterly loss of $0.11 per share, beating the $0.14 consensus loss estimate, while institutional investors own 11.97% of the company.

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating reissued by analysts at BTIG Research in a report released on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock. BTIG Research's price objective would indicate a potential upside of 142.72% from the stock's current price.

GANX has been the subject of a number of other research reports. Weiss Ratings lowered shares of Gain Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 9th. Oppenheimer reaffirmed an "outperform" rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Wall Street Zen upgraded Gain Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, June 21st. HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, July 1st. Finally, Roth Capital reaffirmed a "buy" rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $7.50.

Gain Therapeutics Trading Up 16.4%

Shares of GANX stock opened at $2.06 on Tuesday. Gain Therapeutics has a 12 month low of $1.46 and a 12 month high of $4.34. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. The business's 50 day moving average is $1.79 and its two-hundred day moving average is $1.93. The company has a market cap of $87.86 million, a PE ratio of -3.55 and a beta of 0.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. Equities analysts predict that Gain Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently bought and sold shares of GANX. BlackRock Inc. acquired a new stake in Gain Therapeutics in the 2nd quarter valued at $558,000. GSA Capital Partners LLP bought a new stake in shares of Gain Therapeutics during the 2nd quarter worth approximately $1,283,000. Apollon Wealth Management LLC boosted its holdings in shares of Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company's stock valued at $51,000 after buying an additional 6,675 shares during the last quarter. Millennium Management LLC bought a new position in shares of Gain Therapeutics in the fourth quarter valued at $45,000. Finally, Engineers Gate Manager LP bought a new position in shares of Gain Therapeutics in the fourth quarter valued at $47,000. Institutional investors own 11.97% of the company's stock.

About Gain Therapeutics

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source